Literature DB >> 12356096

International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.

.   

Abstract

The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "E10 Choice of Control Group and Related Issues in Clinical Trials." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance sets forth general principles that are relevant to all controlled trials and are especially pertinent to the major clinical trials intended to demonstrate drug (including biological drug) efficacy. The guidance describes the principal types of control groups and discusses their appropriateness in particular situations. The guidance is intended to assist sponsors and investigators in the choice of control groups for clinical trials.

Entities:  

Mesh:

Year:  2001        PMID: 12356096

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  14 in total

1.  Ethical concerns in schizophrenia research: looking back and moving forward.

Authors:  Scott T Wilson; Barbara Stanley
Journal:  Schizophr Bull       Date:  2005-11-10       Impact factor: 9.306

2.  Noninferiority trials: clinical understandings and misunderstandings.

Authors:  John H Powers; Thomas R Fleming
Journal:  Clin Investig (Lond)       Date:  2013-03-01

Review 3.  Methods and issues in studies of CRE.

Authors:  Scott R Evans; Anthony D Harris
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

Review 4.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials.

Authors:  S Kim; J A Seddon; A J Garcia-Prats; G Montepiedra
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373

6.  Recommendations for reporting outcome results in abdominal wall repair: results of a Consensus meeting in Palermo, Italy, 28-30 June 2012.

Authors:  F E Muysoms; E B Deerenberg; E Peeters; F Agresta; F Berrevoet; G Campanelli; W Ceelen; G G Champault; F Corcione; D Cuccurullo; A C DeBeaux; U A Dietz; R J Fitzgibbons; J F Gillion; R-D Hilgers; J Jeekel; I Kyle-Leinhase; F Köckerling; V Mandala; A Montgomery; S Morales-Conde; R K J Simmermacher; V Schumpelick; M Smietański; M Walgenbach; M Miserez
Journal:  Hernia       Date:  2013-05-15       Impact factor: 4.739

7.  Clinical trials of drugs used off-label in neonates: ethical issues and alternative study designs.

Authors:  Sanjiv B Amin; Michael P McDermott; Adil E Shamoo
Journal:  Account Res       Date:  2008 Jul-Sep       Impact factor: 2.622

8.  Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.

Authors:  Kelly D Getz; Todd A Alonzo; Lillian Sung; Soheil Meshinchi; Robert B Gerbing; Susana Raimondi; Betsy Hirsch; Michael Loken; Lisa Eidenschink Brodersen; Samir Kahwash; John Choi; E Anders Kolb; Alan Gamis; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2021-09-02       Impact factor: 3.167

Review 9.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.

Authors:  Kasia Stepniewska; Nicholas J White
Journal:  Malar J       Date:  2006-12-22       Impact factor: 2.979

10.  The use of external control data for predictions and futility interim analyses in clinical trials.

Authors:  Steffen Ventz; Leah Comment; Bill Louv; Rifaquat Rahman; Patrick Y Wen; Brian M Alexander; Lorenzo Trippa
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.